Methods for the production and cytotoxicity evaluation of KIR2DL NK-receptor antibodies

Details for Australian Patent Application No. 2004253630 (hide)

Owner Novo Nordisk A/S Innate Pharma S.A.S. University of Genoa

Inventors Padkjaer, Soren Berg; Chiesa, Mariella Della; Gauthier, Laurent; Andre, Pascale; Moretta, Alessandro; Wagtmann, Peter Andreas Nicolai Reumert

Agent Shelston IP

Pub. Number AU-B-2004253630

PCT Pub. Number WO2005/003168

Priority 60/483,894 02.07.03 US; 60/545,471 19.02.04 US

Filing date 1 July 2004

Wipo publication date 13 January 2005

Acceptance publication date 25 November 2010

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 9/127 (2006.01) Medicinal preparations characterised by special physical form - Liposomes

G01N 33/569 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for micro-organisms, e.g. protozoa, bacteria, viruses

Event Publications

12 January 2006 PCT application entered the National Phase

  PCT publication WO2005/003168 Priority application(s): WO2005/003168

2 March 2006 Amendment Made

  The nature of the amendment is: Add co-inventor Wagtmann, Peter Andreas Nicolai Reumert

25 November 2010 Application Accepted

  Published as AU-B-2004253630

24 March 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004253641-Pressure-sensitive adhesive composition

2004253610-Lift assembly with cabin electrics integrated in the cabin roof